A Blood-Based Multi-Transcript Test, the NETest, Predicts and Defines PRRT Efficacy in Neuroendocrine Tumors
#1505
Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective NET treatment. Predicting response is based on somatostatin receptor expression and efficacy evaluated by RECIST criteria. Both have limited accuracy. The NETest measures tumor activity in blood and correlates cell signaling and metabolism directly with tumor activity.
Aim(s): Assess the effectiveness of the NETest as a PRRT predictive marker.
Materials and methods: 177Lu-octreotate treated NETs (n=54) followed for 33 months. Histological grade, somatostatin receptor imaging (SRI), CgA (ELISA, normal
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Bodei L
Authors: Bodei L, Kidd M, Severi S, Drozdov I, Nicolini S,
To read the full abstract, please log into your ENETS Member account.